Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Nan Jing, China Clinical Trials

A listing of Nan Jing, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (419) clinical trials

A Study of Napabucasin in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer

This is a Phase III Randomized, Open-Label Clinical Study of Napabucasin (GB201) in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Front-Line Chemotherapy Failure

Phase

0.0 miles

Learn More »

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

This is a Phase II, randomized, multicenter, 2-arm, open-label clinical trial designed to compare the safety and efficacy of RC48-ADC with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), ...

Phase

0.0 miles

Learn More »

A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B

Patents who were treated with NA at least one year and achieved hepatitis B virus (HBV) DNA suppression and HBsAg level<3000 international unit (IU) /mL are enrolled in this study, they are assigned into two groups, in group I, patients will receive pegylated interferon plus entecavir/tenofovir for 48/72/96 weeks, in ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of rhGH (Jintropin ) in Pediatric Participants With ISS

Phase 1: To evaluate the safety and efficacy of 0.05mg/kg/d of rhGH (Jintropin) in the treatment of children with idiopathic short stature (ISS) in 52 weeks. Phase 2: To evaluate the safety and efficacy of rhGH (Jintropin) in the treatment of children with ISS in 2 years

Phase

0.0 miles

Learn More »

Radical Resection of Single-hole Inflatable Mediastinal Mirror Synchronization With Laparoscopic Esophageal Carcinoma

This is a prospective, multicenter, open clinical study in which 155 patients (including 5% shedding rate) who require surgical treatment are scheduled to be included in the study. Prior to any screening process, each subject / legal guardian should sign the informed consent form. Screening tests are used to determine ...

Phase N/A

0.0 miles

Learn More »

STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma

It is a prospective, single-arm, multicenter study. The primary effectiveness endpoint for this clinical trial is 6-month overall objective tumor response (ORR).

Phase N/A

0.0 miles

Learn More »

Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers

This is a prospective, multi-centers, open-label, single-arm study, and the aim of this trial is to evaluate the safety of laparoscopic distal D2 radical gastrectomy for the treatment of locally advanced gastric cancer (cT3-4a, N-/+, M0) after neoadjuvant chemotherapy.

Phase N/A

0.0 miles

Learn More »

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma

The purpose of this study is to evaluate the efficacy and safety of BGB-A317 as second line treatment in patients with advanced unresectable/metastatic ESCC that has progressed during or after first line therapy.

Phase

0.0 miles

Learn More »

D-0120 Safety and PK/PD Study in China

It is a randomized, double-blind, placebo-controlled, multiple-administration, multiple-dose, dose-escalating, phase Ib/IIa clinical study to evaluate the safety, tolerability, PK and PD of D-0120 in healthy subjects and hyperuricemia patients (gout or asymptomatic) in China.

Phase

0.0 miles

Learn More »

Deep Learning Radiomics of MR Imaging for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1802)

Clinically significant portal hypertension (CSPH) is associated with an incremental risk of esophageal varices and overt clinical decompensations in cirrhosis. However, hepatic venous pressure gradient (HVPG) measurement, the gold standard for defining CSPH (HVPG 10mmHg) is invasive and therefore not suitable for routine clinical practice. This is a multi-center diagnostic ...

Phase N/A

0.0 miles

Learn More »